Imbruvica regimen wins FDA approval as first non-chemotherapy treatment for untreated patients with common form of leukemia
In the 10th approval since its 2013 launch, J&J’s cancer drug Imbruvica has secured the FDA nod in combination with Roche’s obinutuzumab in adults with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
